Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Authors
Keywords
-
Journal
Infectious Diseases and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-12
DOI
10.1007/s40121-022-00591-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
- (2021) Ana Paula Streling et al. CLINICAL INFECTIOUS DISEASES
- Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients
- (2021) Barbara Balandin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
- (2021) Abigail M. Rubio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy assessment of PEV2 phage on Galleria mellonella larvae infected with a Pseudomonas aeruginosa dog otitis isolate
- (2021) C. Antoine et al. RESEARCH IN VETERINARY SCIENCE
- Real-world use of ceftolozane/tazobactam: a systematic literature review
- (2021) Laura Puzniak et al. Antimicrobial Resistance and Infection Control
- The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
- (2021) Christian M. Gill et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- (2020) Antonio Vena et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017
- (2020) Sibylle H. Lob et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
- (2020) Alejandro Iregui et al. Microbial Drug Resistance
- Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016–2018
- (2020) Helio S. Sader et al. Microbial Drug Resistance
- In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis
- (2020) Patrick J. Nolan et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
- (2020) Saima Aslam et al. Open Forum Infectious Diseases
- Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing Pseudomonas aeruginosa
- (2020) Michelle Lee et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Challenges in severe community-acquired pneumonia: a point-of-view review
- (2019) Antoni Torres et al. INTENSIVE CARE MEDICINE
- Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients
- (2019) Rachel Yoon Kyung Chang et al. AAPS Journal
- Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient
- (2019) Nancy Law et al. INFECTION
- ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
- (2019) José-Manuel Ortiz de la Rosa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
- (2019) Krisztina M Papp-Wallace et al. JOURNAL OF INFECTIOUS DISEASES
- Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study
- (2019) Pooja Gupta et al. International Journal of Lower Extremity Wounds
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
- (2019) Sandra Mikhail et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
- (2019) Katherine Young et al. BMC MICROBIOLOGY
- Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
- (2019) Y.P. Tabak et al. JOURNAL OF HOSPITAL INFECTION
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Higher MICs (>2 mg/L) Predict 30-day Mortality in patients with Lower Respiratory Tract Infections Caused by Multidrug and Extensively Drug Resistant Pseudomonas aeruginosa Treated with Ceftolozane/Tazobactam
- (2019) O Rodríguez-Núñez et al. Open Forum Infectious Diseases
- Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa: Impact of Antimicrobial Resistance and Bacterial Virulence
- (2019) Raúl Recio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants
- (2019) Pablo Fraile-Ribot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance United States 2015-2017
- (2019) James A. Karlowsky et al. Journal of Global Antimicrobial Resistance
- 2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
- (2019) Delaney E Hart et al. Open Forum Infectious Diseases
- 2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
- (2019) Matthew Mills et al. Open Forum Infectious Diseases
- Resistance to Ceftazidime-Avibactam and Underlying Mechanisms
- (2019) Yuhang Wang et al. Journal of Global Antimicrobial Resistance
- Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
- (2019) Sarah C J Jorgensen et al. Open Forum Infectious Diseases
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016
- (2018) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
- (2018) Laura Escolà-Vergé et al. INFECTION
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
- (2018) Gregory G Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis
- (2018) Gowri Raman et al. Antimicrobial Resistance and Infection Control
- Prevalence and etiology of community-acquired pneumonia in immunocompromised patients
- (2018) Marta Francesca Di Pasquale et al. CLINICAL INFECTIOUS DISEASES
- Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against Pseudomonas aeruginosa: PRIMERS IV
- (2018) Scott R Evans et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The PqsE and RhlR proteins are an autoinducer synthase–receptor pair that control virulence and biofilm development in Pseudomonas aeruginosa
- (2018) Sampriti Mukherjee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
- (2018) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
- (2018) Zheng Pang et al. BIOTECHNOLOGY ADVANCES
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial
- (2018) Patrick Jault et al. LANCET INFECTIOUS DISEASES
- Role of the Multidrug Resistance Efflux Pump MexCD-OprJ in the Pseudomonas aeruginosa Quorum Sensing Response
- (2018) Manuel Alcalde-Rico et al. Frontiers in Microbiology
- 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
- (2018) Akinobu Ito et al. Open Forum Infectious Diseases
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria
- (2017) Vincent H. Tam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Contribution of mexAB-oprM and mexXY ( -oprA ) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran
- (2016) Hamid Reza Goli et al. INFECTION GENETICS AND EVOLUTION
- Adaptive resistance to antibiotics in bacteria: a systems biology perspective
- (2016) Santiago Sandoval-Motta et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
- (2016) Celeste Vinluan et al. Drug Design Development and Therapy
- Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
- (2016) Elizabeth (Betsy) Hirsch et al. Therapeutics and Clinical Risk Management
- Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
- (2016) Benjamin K. Chan et al. Scientific Reports
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
- (2015) S. D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination
- (2015) Jonathan C. Cho et al. PHARMACOTHERAPY
- Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa
- (2015) Jürg Dreier et al. Frontiers in Microbiology
- Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
- (2014) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards the development of novel anti-biofilm therapies
- (2014) Patrick K. Taylor et al. JOURNAL OF BIOTECHNOLOGY
- Bacterial Persister Cell Formation and Dormancy
- (2013) Thomas K. Wood et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China
- (2013) Zhi-li Fang et al. INFECTION GENETICS AND EVOLUTION
- Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control
- (2013) S. T. Rutherford et al. Cold Spring Harbor Perspectives in Medicine
- Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
- (2012) P. D. Tamma et al. CLINICAL MICROBIOLOGY REVIEWS
- Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance
- (2012) L. Fernandez et al. CLINICAL MICROBIOLOGY REVIEWS
- Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
- (2012) Hui Li et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection
- (2011) E.-J. Joo et al. INFECTION
- Health Care-Associated Pneumonia (HCAP)
- (2011) Scott T. Micek et al. MEDICINE
- Pseudomonas aeruginosa: all roads lead to resistance
- (2011) Elena B.M. Breidenstein et al. TRENDS IN MICROBIOLOGY
- Persister Cells
- (2010) Kim Lewis Annual Review of Microbiology
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phage Therapy in Clinical Practice: Treatment of Human Infections
- (2010) Elizabeth Kutter et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Aminoglycoside modifying enzymes
- (2010) Maria S. Ramirez et al. DRUG RESISTANCE UPDATES
- Emergence of Pseudomonas aeruginosa Strains Producing High Levels of Persister Cells in Patients with Cystic Fibrosis
- (2010) L. R. Mulcahy et al. JOURNAL OF BACTERIOLOGY
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case–control study
- (2009) M. Montero et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started